News Releases

News Releases

Date Title
May 4, 2021 Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™
Company appoints experienced commercial leader, Lisa LaMond , to oversee sales strategy and execution Selected Syneos Health ® as partner for field sales execution in the US Company remains on track for potential approval in the US in August 2021 CAMBRIDGE, Mass.
May 3, 2021 Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company’s management team will host a conference call to review operating
Apr 16, 2021 Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to four new employees in connection with
Apr 8, 2021 Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 8, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity “Horizons in
Apr 7, 2021 Sesen Bio Announces Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend “FOR” Proposal to Increase Authorized Shares
Strong balance sheet: Approximately $110 million in cash and cash equivalents as of March 31, 2021 1 Company remains on-track for potential product approvals in US in August 2021 and in Europe in early 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 7, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage
Mar 22, 2021 Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum™
IND approval triggers $3 million milestone payment to Sesen Bio Product market application expected to be submitted to the National Medical Product s Administration in 2022 with potential approval in 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage
Mar 22, 2021 Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to three new employees in connection with
Mar 15, 2021 Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™
Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021 1 Biologics License Application accepted by the FDA under Priority Review Marketing Authorization Application submitted in Europe with potential approval in early 2022   Company to host conference call at
Mar 8, 2021 Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™
Follows U.S. FDA acceptance of the Biologics License Application under Priority Review Potential approval in Europe anticipated in early 2022 Significant commercial opportunity in Europe with projected peak revenue of $450M-$1.1B CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar.
Mar 2, 2021 Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company’s Lead Product Candidate Vicineum™
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 2, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conference call with Dr.
Displaying 1 - 10 of 14

© 2021 Sesen Bio. All Rights Reserved.

Top